Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Radioligand therapies in cancer: mapping the educational landscape in Europe.

European journal of nuclear medicine and molecular imaging·2023

Same author

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.

International journal of molecular sciences·2023

Same author

What Is Theranostics?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023

Same author

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023

Same author

Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times.

European radiology·2023

Same author

Superior Tumor Detection for <sup>68</sup>Ga-FAPI-46 Versus <sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023

Search research articles

Related Experiment Video

Updated: May 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

CD70-targeted cancer theranostics: Progress and challenges.

Weijun Wei¹, Viktor Grünwald², Ken Herrmann³

¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai 200127, China.

Med (New York, N.Y.)

|April 18, 2025

Summary

CD70 imaging shows promise for diagnosing and treating cancers like clear cell renal cell carcinoma. Novel tracers precisely detect CD70-expressing tumors, guiding personalized immunotherapies and improving patient outcomes.

Keywords:

CD70 clear cell renal cell carcinoma immunoPET theranostics

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: May 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Molecular Imaging
Immunotherapy

Background:

CD70 is a tumor antigen overexpressed in clear cell renal cell carcinoma (ccRCC), nasopharyngeal carcinoma, and lymphoma.
CD70 expression is minimal in healthy tissues, making it a specific target.
CD70 is a promising biomarker for advanced cancer diagnostics and therapeutics.

Purpose of the Study:

To evaluate CD70-targeted immunoPET imaging for diagnosing ccRCC metastases.
To assess the utility of CD70 imaging in patient selection for immunotherapies.
To explore the potential of CD70-targeted radiotheranostics.

Main Methods:

Development and application of single-domain antibody-derived tracers ([18F]RCCB6, [68Ga]Ga-NOTA-RCCB6) for immunoPET imaging.
Utilizing CD70 expression levels for patient stratification in targeted therapies.
Investigating radiolabeled tracers for simultaneous diagnosis and treatment (radiotheranostics).

Main Results:

ImmunoPET imaging with CD70 tracers demonstrated high diagnostic precision for ccRCC metastases.
CD70 imaging accurately identified common and rare metastatic sites, improving staging.
CD70 expression levels effectively stratified patients for CAR-T cell and ADC therapies.

Conclusions:

CD70-targeted immunoPET imaging enhances diagnostic accuracy and staging for ccRCC.
CD70 imaging is crucial for optimizing patient selection and monitoring response to immunotherapies.
Radiotheranostic approaches targeting CD70 offer new avenues for precise cancer management.